Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss

Sponsor
Provident Clinical Research (Other)
Overall Status
Completed
CT.gov ID
NCT00692731
Collaborator
Kao (Taiwan) Corporation (Industry)
132
2
14
66
4.7

Study Details

Study Description

Brief Summary

The primary objective of this trial is to evaluate the influence of consuming a tea catechin containing sports beverage on body fat mass during exercise-induced weight loss among overweight and obese men and women.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: 500 mL/day of a beverage providing approximately 625 mg catechins
  • Other: Control beverage matched for energy and caffeine content

Detailed Description

The study will include two screening/baseline visits and six treatment visits over 12 weeks. During the treatment phase of the study, subjects will be instructed to consume one bottle of sports drink (500 ml) daily (total consumption of tea catechins in the active group = 540 mg/d). Subjects will be asked to maintain a constant energy intake throughout the study period. Three-day diet records will be collected and analyzed at weeks 0, 6, and 12 to evaluate consistency of energy intake.

All subjects will engage in an exercise program with a goal of maintaining 180 min/week of low- to moderate-intensity exercise (e.g., walking and other aerobic activities, 4-6 days per week). Three of the weekly exercise sessions will be supervised and 1-3 will be unsupervised. Subjects will be asked to wear a pedometer and record their daily physical activity (steps) each night in a physical activity diary. Diaries will be collected at each visit and used to evaluate exercise compliance. Dual energy X-ray absorptiometry (DEXA) and computed tomography (CT) scans will be performed at baseline (week 0) and at the end of the treatment (week 12). Additionally, body weight and abdominal circumference will be assessed at every clinic visit during the study. It is anticipated that subjects will expend 1000-1800 kcal per week above their baseline level in deliberate physical activity. Accordingly, the control group is expected to lose 1.5 to 2.8 kg of body fat during the 12-week treatment period

Study Design

Study Type:
Observational
Actual Enrollment :
132 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Randomized, Double-Blind, Controlled Study to Assess the Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss
Study Start Date :
Jun 1, 2006
Actual Primary Completion Date :
Jul 1, 2007
Actual Study Completion Date :
Aug 1, 2007

Arms and Interventions

Arm Intervention/Treatment
Active

Tea catechin sport beverage

Dietary Supplement: 500 mL/day of a beverage providing approximately 625 mg catechins
Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins

Control

Control beverage

Other: Control beverage matched for energy and caffeine content
500 mL/day of a control beverage

Outcome Measures

Primary Outcome Measures

  1. Changes in body fat mass. [Baseline to end-of-treatment]

Secondary Outcome Measures

  1. Changes in body weight [Baseline to end-of-treatment]

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Men and women 21 to 65 years of age, inclusive

  • Waist circumference ≥ 87 cm for women and ≥ 90 cm for men at screening

  • Total cholesterol ≥ 200 mg/dL

  • Provide written informed consent and authorization for protected health information

Exclusion Criteria:
  • Volunteers with Body mass index ≥ 40.0 kg/m2 or < 25.0 kg/m2;

  • Recent weight loss of more than 4.5 kg;

  • Recent use of any weight loss medications, supplements, or programs;

  • History of weight-reducing surgery or an eating disorder

  • Pregnancy

Contacts and Locations

Locations

Site City State Country Postal Code
1 Meridien Research St Petersburg Florida United States 33709
2 Provident Clinical Research Bloomington Indiana United States 47403

Sponsors and Collaborators

  • Provident Clinical Research
  • Kao (Taiwan) Corporation

Investigators

  • Study Director: Kevin C Maki, PhD, Provident Clinical Research

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT00692731
Other Study ID Numbers:
  • PRV-06001
First Posted:
Jun 6, 2008
Last Update Posted:
Jun 6, 2008
Last Verified:
Jun 1, 2008
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 6, 2008